Reports Q2 revenue $4.651M, consensus $6.19M. “In the second quarter of 2023, we achieved two important milestones in our Phase 2a clinical trials that support our efforts in developing AB-729 (imdusiran), our lead RNAi therapeutic, as a cornerstone therapy in a functional cure treatment regimen for HBV,” said William Collier, Arbutus President and Chief Executive Officer. “First, we reported data from our Phase 2a clinical trial showing that imdusiran in combination with interferon, is well tolerated and appears to result in continued HBsAg declines in some patients. Second, we made solid progress towards our goal of further stimulating host HBV-associated immunity, as we dosed the first patient in the additional treatment arm of the ongoing Phase 2a trial assessing the addition of low-dose nivolumab, a PD-1 monoclonal antibody, to VTP-300 and imdusiran.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABUS:
- Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
- Is ABUS a Buy, Before Earnings?
- Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
- Arbutus Biopharma appoints Rewolinski to board of directors
- Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors